Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients
Latest Information Update: 09 Dec 2020
Price :
$35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Dermatomyositis
- Focus Proof of concept; Therapeutic Use
- Acronyms STIR
- 01 Dec 2020 Primary endpoint of Number of participants who achieve International Myositis Assessment and Clinical Studies Definition of Improvement has been met according to results published in the Arthritis and Rheumatology.
- 01 Dec 2020 Results published in the Arthritis and Rheumatology
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.